AMG National Trust Bank Has $4.96 Million Stake in Zimmer Biomet Holdings, Inc. $ZBH

AMG National Trust Bank lifted its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 29.1% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 50,359 shares of the medical equipment provider’s stock after buying an additional 11,339 shares during the quarter. AMG National Trust Bank’s holdings in Zimmer Biomet were worth $4,960,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Dodge & Cox increased its stake in shares of Zimmer Biomet by 12.9% during the 2nd quarter. Dodge & Cox now owns 22,097,463 shares of the medical equipment provider’s stock worth $2,015,510,000 after purchasing an additional 2,533,009 shares during the last quarter. Norges Bank bought a new stake in Zimmer Biomet in the second quarter worth $225,867,000. AQR Capital Management LLC increased its position in Zimmer Biomet by 276.6% during the second quarter. AQR Capital Management LLC now owns 1,300,593 shares of the medical equipment provider’s stock worth $118,627,000 after buying an additional 955,284 shares during the last quarter. Franklin Resources Inc. raised its holdings in Zimmer Biomet by 15.2% during the second quarter. Franklin Resources Inc. now owns 4,673,860 shares of the medical equipment provider’s stock valued at $426,303,000 after buying an additional 615,014 shares in the last quarter. Finally, Invesco Ltd. lifted its position in shares of Zimmer Biomet by 11.5% in the second quarter. Invesco Ltd. now owns 4,606,591 shares of the medical equipment provider’s stock worth $420,167,000 after buying an additional 475,921 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Price Performance

Shares of Zimmer Biomet stock opened at $98.74 on Friday. The firm has a market cap of $19.57 billion, a P/E ratio of 27.89, a price-to-earnings-growth ratio of 2.03 and a beta of 0.62. The firm’s 50-day simple moving average is $90.64 and its 200-day simple moving average is $95.82. Zimmer Biomet Holdings, Inc. has a twelve month low of $84.59 and a twelve month high of $114.44. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.10 and a current ratio of 1.98.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The firm had revenue of $2.24 billion during the quarter, compared to analysts’ expectations of $2.22 billion. During the same quarter last year, the company earned $2.31 earnings per share. The company’s revenue for the quarter was up 10.9% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. As a group, research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, January 30th. Shareholders of record on Tuesday, December 30th were given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date was Tuesday, December 30th. Zimmer Biomet’s dividend payout ratio is 27.12%.

Analysts Set New Price Targets

A number of research analysts have recently commented on ZBH shares. Citigroup reissued a “buy” rating on shares of Zimmer Biomet in a report on Wednesday, February 11th. Canaccord Genuity Group cut their price objective on Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating for the company in a research report on Monday, November 10th. The Goldman Sachs Group downgraded Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 target price for the company. in a research note on Friday, January 9th. Wells Fargo & Company upped their price target on Zimmer Biomet from $93.00 to $98.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 11th. Finally, Barclays lowered their price objective on shares of Zimmer Biomet from $104.00 to $100.00 and set an “underweight” rating on the stock in a research note on Thursday, February 12th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, ten have given a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $106.20.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.